FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 111 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR How you can do your part in the AI transformation of... October 7, 2025 FDA Approves New Dosing Regimen for Cetuximab April 13, 2021 Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 EMA Adopts Positive Opinion for Pemetrexed Baxter November 3, 2022 Load more HOT NEWS Gym Offers Free Membership & Support To Those Struggling With Addiction 15% of People With Lung Cancer Have an Inherited Mutation for... Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... Does Eating Processed Meat Increase Your Risk for Cancer?
